MicroRNA-205 increases the sensitivity of docetaxel in breast cancer

Oncology Letters

Volumn 11, Issue 2, 2016, Pages 1105-1109

  Cai, Yang ^a   Yan, Xiang ^a   Zhang, Guoqing ^a   Zhao, Weihong ^a   Jiao, Shunchang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; Docetaxel; miR 205

Indexed keywords

DOCETAXEL; GREEN FLUORESCENT PROTEIN; MICRORNA 205;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL LINE; CELL CULTURE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; COLONY FORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR XENOGRAFT;

EID: 84954342231     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.4030     Document Type: Article

References (21)

1. Azambuja E, Durbecq V, Rosa DD, Colozza M, Larsimont D, Piccart-Gebhart M and Cardoso F: HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 19: 223-232, 2008
2. World Health Organization: World Cancer Report 2008. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf. Accessed February 26, 2011.
3. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al (eds): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed May 20, 2013.
4. Cancer Facts & Figures 2012. American Cancer Society, Atlanta, p4, 2012.
5. He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004.
6. Khoshnaw SM, Green AR, Powe DG and Ellis IO: MicroRNA involvement in the pathogenesis and management of breast cancer. J Clin Pathol 62: 422-428, 2009.
7. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM and Tagliabue E: MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res 69: 2195-2200, 2009.
8. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130: 2113-2129, 2006.
9. Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336, 2007.
10. Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359, 2008.
11. Adams BD, Furneaux H and White BA: The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21: 1132-1147, 2007.
12. Kondo N, Toyama T, Sugiura H, Fujii Y and Yamashita H: MiR-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68: 5004-5008, 2008.
13. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152, 2008.
14. Wang N, Li Q, Feng NH, Cheng G, Guan ZL, Wang Y, Qin C, Yin CJ and Hua LX: MiR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian J Androl 15: 735-741, 2013.
15. Wu H, Zhu S and Mo YY: Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 19: 439-448, 2009.
16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005.
17. Slamom DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. J Engl J Med 344: 783-792, 2001.
18. Burris HA: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9 (Suppl 3): 10-5, 2004
19. Higa GM and Abraham J: Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 7: 1183-1192, 2007.
20. [no authors listed]: Breast cancer drug approved for new indication. Womens Health (Lond Engl) 6: 173, 2011.
21. Kastl L, Brown I and Schofield AC: MiRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 131: 445-454, 2012.